PriceTargets.com logo

Entera Bio - ENTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 491.72%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.69 As of 07/26/2024 01:00 AM ET
▼ -0.05 (-2.87%)

This chart shows the closing price for ENTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Entera Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ENTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENTX

Analyst Price Target is $10.00
▲ +491.72% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Entera Bio in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 491.72% upside from the last price of $1.69.

This chart shows the closing price for ENTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Entera Bio. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00Low
5/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
4/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
12/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
9/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
4/4/2023HC WainwrightReiterated RatingBuy$10.00Low
3/28/2023HC WainwrightReiterated RatingBuy$10.00Low
9/6/2022HC WainwrightInitiated CoverageBuy$10.00Low
7/19/2022B. RileyLower TargetBuy$6.00 ➝ $5.00Low
1/24/2022B. RileyLower Target$11.00 ➝ $6.00High
10/7/2021B. RileyLower TargetBuy$14.00 ➝ $11.00Low
7/12/2021AegisReiterated RatingBuy$12.00Low
6/24/2021B. RileyBoost TargetBuy$9.00 ➝ $14.00Low
6/16/2021B. RileyInitiated CoverageBuy$9.00High
3/22/2021AegisInitiated CoverageBuy$12.00Medium
3/11/2021Maxim GroupBoost TargetBuy$5.00 ➝ $10.00High
7/24/2020Maxim GroupReiterated RatingBuyLow
9/24/2019Maxim GroupSet TargetBuy$8.00Low
8/20/2019Maxim GroupSet TargetBuy$8.00Low
7/31/2019Maxim GroupSet TargetBuy$8.00N/A
(Data available from 7/26/2019 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2024
  • 0 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2024
  • 7 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024

Current Sentiment

  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Entera Bio logo
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Read More

Today's Range

Now: $1.69
Low: $1.65
High: $1.75

50 Day Range

MA: $2.02
Low: $1.64
High: $2.44

52 Week Range

Now: $1.69
Low: $0.52
High: $3.35

Volume

61,448 shs

Average Volume

160,341 shs

Market Capitalization

$60.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Entera Bio?

The following sell-side analysts have issued research reports on Entera Bio in the last twelve months: HC Wainwright.
View the latest analyst ratings for ENTX.

What is the current price target for Entera Bio?

1 Wall Street analysts have set twelve-month price targets for Entera Bio in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 491.7%. HC Wainwright has the highest price target set, predicting ENTX will reach $10.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $10.00 for Entera Bio in the next year.
View the latest price targets for ENTX.

What is the current consensus analyst rating for Entera Bio?

Entera Bio currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ENTX will outperform the market and that investors should add to their positions of Entera Bio.
View the latest ratings for ENTX.

What other companies compete with Entera Bio?

Other companies that are similar to Entera Bio include Molecular Partners, Genfit, Monte Rosa Therapeutics, Century Therapeutics and Caribou Biosciences. Learn More about companies similar to Entera Bio.

How do I contact Entera Bio's investor relations team?

Entera Bio's physical mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The company's listed phone number is (722) 532-7151 and its investor relations email address is [email protected]. The official website for Entera Bio is www.enterabio.com. Learn More about contacing Entera Bio investor relations.